We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Virbac SA (VIRP) EUR1.25

Sell:€338.00 Buy:€352.00 Change: €7.50 (2.22%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:€338.00
Buy:€352.00
Change: €7.50 (2.22%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:€338.00
Buy:€352.00
Change: €7.50 (2.22%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. It also offers food and electronic identification chips for pets.

Contact details

Address:
13eme rue LID, Bp 27, Carros Cedex
CARROS
06510
France
Telephone:
+33 (4) 92087100
Website:
https://corporate.virbac.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VIRP
ISIN:
FR0000031577
Market cap:
€2.93 billion
Shares in issue:
8.44 million
Sector:
Pharmaceuticals
Exchange:
Euronext Paris
Country:
France
Currency:
Euro
Indices:
n/a

Key personnel

  • Marie-Helene Dick-Madelpuech
    Chairwoman of the Board of Directors
  • Sebastien Huron
    Chief Executive Officer, Member of the Group Executive Committee
  • Habib Ramdani
    Deputy Chief Executive Officer, Chief Financial Officer, Member of the Group Executive Committee
  • Marc Bistuer
    Deputy Chief Executive Officer - Qualified Person, Head - Global Industrial Operations and Corporate Quality Assurance, Member of the Group Executive Committee
  • Pierre Madelpuech
    Vice Chairman of the Board of Directors
  • Francesca Cortella
    Head - Corporate Human Resources, Member of the Group Executive Committee
  • Sophie Favini
    Head of Global Business Operations, Member of the Executive Committee
  • Bertrand Havrileck
    Head - Corporate Research and Development, Biological and Pharmaceuticals, Member of the Group Executive Committee
  • Nathalie Pollet
    Head - Global Marketing and Market Development, Member of the Group Executive Committee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.